


Analysis Report



Olink[®] Target 96

PROJECT NAME

Olink Target 96 Demo

ISSUE DATE

2022-05-23

CUSTOMER

Customer Name

customer.name@customer.com

BUSINESS DEVELOPMENT MANAGER

BDM Manager

bdm.manager@olink.com

ANALYSIS LAB

Analysis Service Uppsala

itsupport@olink.com

1. Project information

Olink panel	No. of Samples	No. of Plates	Normalization Method
Target 96 Oncology II	264	3	Intensity Normalized (v.2)

1.1 Sample type

EDTA plasma

2. Quality control

Four internal controls are added to each sample to monitor the quality of assay performance, as well as the quality of individual samples. The quality control (QC) is performed in two steps:

1. Each sample plate is evaluated on the standard deviation of the internal controls. This should be below 0.2 NPX. Only data from sample plate that pass this quality control will be reported.
2. The quality of each sample is assessed by evaluating the deviation from the median value of the controls for each individual sample. Samples that deviate less than 0.3 NPX from the median pass the quality control.

Data from all samples is included in the data output file. Samples that did not pass the QC are indicated in columns named "QC Warning". Data points from samples that do not pass QC should be treated with caution. [See 4]

2.1 Summary of Quality Control

Olink panel	No. of samples that passed QC / Tot no. of samples	Passed samples (%)
Target 96 Oncology II	262 / 264	99

2.2 Intra- and Inter-Assay Coefficient of Variance (%CV)

Intra and inter CVs are based on control samples (pooled plasma samples) included on each plate. Calculations are made using linear NPX-values. The number of assays with CVs within defined intervals are presented.

2.2.1 Average %CV

Olink panel	Intra-Assay %CV Reference intra CV <15%	Inter-Assay %CV Reference inter CV <25%
Target 96 Oncology II	5	7

2.2.2 Intra-Assay %CV Distribution

Olink panel	No. of proteins with %CV within defined intervals				N/A
	<5%	≥5 - <10%	≥10 - <15%	≥15%	
Olink Target 96 Oncology II	49	42	0	1	0

2.2.3 Inter-Assay %CV Distribution

Olink panel	No. of proteins with %CV within defined intervals				N/A
	<10%	≥10 - <20%	≥20 - <30%	≥30%	
Olink Target 96 Oncology II	75	15	2	0	0

3. Protein detection results

3.1 Number of proteins detected in >75% of the samples

Olink panel	No. of detected proteins / Tot no. of proteins	Detected proteins (%)	Expected detectability in EDTA plasma* (%)
Target 96 Oncology II	92 / 92	100	>90

*The expected detectability is based on EDTA plasma from healthy donors. These values are intended as guidelines only and protein levels may vary depending on different pathological conditions, sample matrices, or sample preparation methods.

3.2 Data output

Data is presented as normalized protein expression (NPX) values, Olink Proteomics' arbitrary unit on log2 scale. [See 4]

The NPX values are presented in a separate data file. Data points for samples that did not pass QC are written in red text. Data values for measurements below limit of detection (LOD) are reported for all samples. Cells containing data values below LOD are indicated with a pink background. [See 4]

4. Further information

Collection of direct links to pages containing important information relating to Olink data generation and processing, as well as additional support content:

<https://www.olink.com/key-links/>

5. Samples that did not pass QC

Target 96 Oncology II

Sample ID
bf5e1a8c9ef8 x
58c8ddd7bd10 x